LONDON (Alliance News) - Cancer immunotherapies developer Scancell Holdings PLC on Thursday said it has signed an agreement with Belgian contract manufacturing organisation Eurogentec SA covering the manufacturing of new supplies of Scancell's SCIB1 vaccine.
Scancell said the Eurocgentec-manufactured SCIB1 batch will be used in a US clinical study expected to start in 2017.
"This new supply will not only be used in our upcoming US checkpoint inhibitor combination trial, but also enable us to recommence treating patients in the long-term extension of the Phase 1/2 study," said Richard Goodfellow, Scancell's chief executive.
Shares in Scancell were untraded on Thursday, having last traded at 18.50 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)